Genmab’s latest phase 2 data spur claim ADC is ‘clearly superior’ to AbbVie’s Elahere

Genmab unveiled Phase 2 RINA‑S (Rinatabart Sesutecan) results in platinum‑resistant ovarian cancer, reporting durable and clinically meaningful responses. The data were first disclosed in a Business Wire release, which also noted Lilly’s Jaypirca label expansion. The announcement positions Genmab to capture market share from existing antibody‑drug conjugates, while AbbVie’s Elahere faces a potential challenger.

A successful rollout would erode AbbVie’s share of the ADC market in this indication. Subsequent coverage expanded the interpretation. Endpoints News and The Pharma Letter highlighted the durability of responses, and European Biotechnology Magazine linked the results to the $1.8 billion ProfoundBio investment, underscoring the financial stakes.

Fierce Biotech framed the findings as evidence that Genmab’s ADC platform is “clearly superior” to AbbVie’s Elahere, suggesting a competitive edge in the platinum‑resistant ovarian cancer space. The claim rests on early comparative data rather than head‑to‑head trials. Further trials are slated to confirm whether Genmab can translate these outcomes into market approval and challenge AbbVie’s position.